By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The combination of dutasteride and tamsulosin is used to treat men who have symptoms of an enlarged prostate gland, also known as benign prostatic hyperplasia (BPH). Benign enlargement of the prostate is a common condition in men as they age. The prostate gland is found beneath the bladder.
Dutasteride/tamsulosin, also known as Jalyn, is a medicine manufactured by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH). It is a combination of two previously available medications: dutasteride (Avodart) and tamsulosin (Flomax). It has 0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride in it.
The Global tamsulosin dutasteride market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. With a prevalence of 50% by the sixth decade of life, benign prostatic hyperplasia (BPH) is a common source of symptoms relating to the lower urinary system. Lower urinary tract symptoms (LUTS), urinary tract infections, and acute urine retention are all caused by hyperplasia of the stromal and epithelial prostatic components that surround the urethra.
Symptomatic BPH can be treated medically with 5-reductase inhibitors, 1-adrenergic antagonists, or a 5-reductase inhibitor plus a 1-adrenergic antagonist combination. Selective 1-adrenergic antagonists reduce the barrier to urine flow without reducing bladder contractility by relaxing the smooth muscles of the prostate and bladder neck without damaging the detrusor muscle of the bladder wall.
According to clinical trials, 1-adrenergic antagonists improve LUTS and boost urine flow rates in men with symptomatic BPH, but they have no effect on the long-term risk of urinary retention or the requirement for surgical intervention.
Inhibitors of 5-reductase reduce the amount of dihydrotestosterone produced inside the prostate, which leads to lower prostate volumes, improved peak urine flow rates, symptom alleviation, and a decreased risk of acute urinary retention and the necessity for surgical intervention.
The 5-reductase inhibitor dutasteride and the 1-adrenergic antagonist tamsulosin show considerable improvements from baseline compared to either treatment alone, according to preliminary findings of the current Combination of Avodart and Tamsulosin (CombAt) research.
